In a letter from our CEO to shareholders, Eric Lefkofsky addresses our long-term commitment to the mission of bringing AI to healthcare in order to help patients live longer and healthier lives. Read the full letter here: https://tempus.co/3SCFI0J
Tempus AI
Biotechnology Research
Chicago, IL 75,505 followers
Tempus is advancing data-driven precision medicine with the practical application of AI in healthcare. It’s About Time.
About us
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).
- Website
-
http://www.tempus.com
External link for Tempus AI
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Chicago, IL
- Type
- Privately Held
- Founded
- 2015
Locations
Employees at Tempus AI
Updates
-
Today we shared our first quarterly earnings since becoming a public company. In Q2, - Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 - Data licensing revenue growth accelerated to 40% year-over-year - We expanded into the minimal residual disease (MRD) market with the launch of both tumor-naïve and tumor-informed assays - We established a joint venture with Softbank to enter the Japanese market - We raised $410.7 million of gross proceeds in initial public offering Read our full earnings report here: https://tempus.co/4fCq3bq
-
Tempus One continues to evolve, providing enhanced features and cutting-edge technology to support your clinical needs. Features to streamline your workflow include rapid filtering and the ability to order specimen collection kits inside of One. Explore Tempus One here: https://tempus.co/4cqQNJv
-
A new Next program is now available, focused on the identification of care gaps associated with HER2 testing recommended under clinical guidelines for patients with select metastatic cancers. We’re able to support physicians in closing this specific care gap with an algorithm that runs as part of xR, our RNA sequencing assay, to help surface patients who are particularly likely to benefit from on-guideline IHC testing. Learn more: https://tempus.co/4c55P7f
-
We now have over one million records with matched clinical and genomic data. This dataset is unique to Tempus and allows us to support the critical research and development of the next generation of cancer treatments. Explore our data offerings: https://tempus.co/3Sr1413
-
July is Minority Mental Health Month, a time to recognize and address the unique mental health challenges faced by minority communities. This month serves as a reminder to celebrate diversity, and advocate for equitable mental health care. Explore our offerings to bring personalized medicine to mental health: https://tempus.co/3zSxZoC
-
A recent case study highlights the implementation of Tempus Next at St. Francis Hospital and Heart Center to identify patients with severe Aortic Stenosis (AS) who had not previously been receiving guideline-recommended care. Tempus Next uses AI, including natural language processing, to contextualize patients in real-time using precise patient screening parameters to identify potentially undertreated or untreated patients. Read on: https://tempus.co/3Yb0gRB
-
We've created one of the world’s largest libraries of human ex vivo tumor organoids with rich clinical and molecular characterization. We're now offering our biopharma customers an opportunity to screen their pre-clinical candidates against 60 organoids that span 10 different cancer indications, and rapidly generate multimodal data to inform drug development programs. To learn more, click here: https://tempus.co/3WvYKbC
-
Join us for an upcoming webinar, "Integrating Omics in R&D: A new era of biomedical research,” on July 31 at 11 AM CT. Speakers Nike Beaubier, MD, Calvin Chao, MD, and Dr. M. Sharon Stack, PhD will discuss the transformative role of multi-omics in understanding complex disease mechanism and will dive into the integration of diverse omics data, from NGS to proteomics, in research. Register here: https://tempus.co/3Y8HGcK
-
We’re excited to announce that our multimodal immune profile score (IPS) algorithmic test is now available for RUO. IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. IPS is a pan-cancer, laboratory developed test that assesses a combination of immunotherapy-related biomarkers from prior DNA and RNA test results to calculate an IPS from 0-100 and a classification of either IPS-Low or IPS-High. Learn more: https://tempus.co/3y7ylHp